

Prevalence and Predictors of Non-Alcoholic Liver Disease on MRI Among Patients with Crohn's Disease

Qijin Hong

Shanghai Jiao Tong University

Qi Feng

Shanghai Jiao Tong University

Jun Shen

Shanghai Jiao Tong University

Qing Zheng

Shanghai Jiao Tong University

Yuqi Qiao (✉ qiaoyuqi1984@163.com)

Shanghai Jiao Tong University

Research Article

Keywords: Crohn's disease, non-alcoholic fatty liver disease, magnetic resonance imaging, Inflammatory bowel disease, prevalence, prediction

Posted Date: January 21st, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1223753/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Version of Record: A version of this preprint was published at BMC Gastroenterology on April 12th, 2022. See the published version at <https://doi.org/10.1186/s12876-022-02238-5>.

Abstract

Background: It has been documented that Crohn's disease patients were prone to develop non-alcoholic liver fatty liver disease with less metabolic factors. Our purpose is to investigate the prevalence, clinical characteristics and possible indicators for NAFLD in a cohort of Chinese patients with Crohn's disease.

Methods: Established Crohn's disease (CD) patients who underwent magnetic resonance enterography (MRE) at the gastroenterology unit of our hospital were consecutively enrolled between June 2018 to May 2020. The diagnosis of NAFLD was made by magnetic resonance proton density fat fraction (MR-PDFF) maps. Medical records during hospitalization were collected and examined by univariate and multivariate analyses. Then a predictive model was constructed based on logistic regression analysis to evaluate the risk of developing NAFLD.

Results: A total of 340 CD subjects were enrolled in this study, 83 (24.4%) suffered from NAFLD. Compared with those without NAFLD, patients with NAFLD showed longer disease duration, higher BMI, more frequent use of corticosteroid and pronouncedly elevated liver function tests. The comparison showed no difference in terms of prolonged anti TNF- α use (>54w). Multivariate analysis demonstrated that BMI, ALT, AST and GGT could independently predict hepatic steatosis.

Conclusion: NAFLD is frequent in chronic CD patients, while long term use of anti TNF- α seems to have no impact on the development of NAFLD in this population. The model incorporating duration, serum transaminase and body mass index presented as a clinical nomogram could well predict the risk of NAFLD in patient with CD.

1. Introduction

Crohn's disease (CD) is a subtype of inflammatory bowel disease (IBD) that characterized by discontinuous and ulcerous transmural inflammation of the intestinal tract[1]. Since the "regional ileitis" was formally reported in 1932, there has been over 1,000,000 people in the United States and 2,500,000 in Europe respectively that estimated to have IBD[2]. Although the etiology of Crohn's disease remains unclear, the widely use of biological drugs with different mechanisms has change the phenotype of CD[3]. 65–76% of CD patients have been reported to have weight loss, because it can involve any part of the digestive tract, mainly the small bowel[4]. However, increasing observing studies have reported that NAFLD is highly prevalent in CD patients, with less metabolic factors[5][6]

Non-alcoholic fatty liver disease (NAFLD), a spectrum of liver disorders, affects nearly a quarter of global population, which is also gaining rising incidence in the Asian area[7]. There is now growing evidence that NAFLD is a multisystem disease, which affects both extra-hepatic organs and regulatory pathways[8]. It increases risk of type 2 diabetes mellitus (T2DM), cardiovascular and cardiac diseases, and chronic kidney disease (CKD)[9]. McHenry et al pointed out that Crohn's disease patients have more than double the risk of NAFLD compared with the general population after considering traditional risk factors[5]. They also constructed a clinical prediction tool to help screen NAFLD, although they admitted the limitation of race and ethnicity[10].

The discrepancies have been recognized between eastern and western population regarding the phenotypes and natural history of IBD[11]. While NAFLD is largely asymptomatic until end-stage complications occur[12]. Hence, early diagnosis and intervention are pivotal in the management of this co-exist disease. Therefore, the main aim of this article was to evaluate prevalence of NAFLD in CD patients using a Chinese cohort, then to construct a prediction model for risk of NAFLD.

2. Design/methods

2.1. Patients

Inpatients diagnosed with Crohn's disease (CD) at the gastroenterology unit of Shanghai Renji Hospital were consecutively enrolled between August 2020 to May 2021. During the hospitalization, each patient underwent magnetic resonance imaging,

at the time of which medical records were collected. Clinical parameters including gender, age, disease behavior, body mass index (BMI), history of medication, as well as laboratory examination results were derived from medical records. The exclusion criteria included excessive alcohol consumption, suspected tuberculosis infection or any other liver diseases. The ethics review board of Renji Hospital, School of Medicine, Shanghai Jiaotong University approved this study (KY-2021-122-B), and informed consent was waived due to the retrospective nature.

2.2. Definition

CD patients in this study were diagnosed based on the ECCO consensus[13] by an multi-disciplinary team (MDT) of experienced experts at our center. Endoscopic and radiological examinations were both taken into account.

The diagnosis of NAFLD was made by using MRI-PDFF, conducted by expert radiologists who has >5 years of abdominal imaging experience and who were blinded to the clinical history and laboratory details of patients during the time of examination. MR imaging was performed using a 1.5T GE scanner with an 8-channel, torso phased-array coil (Optima MR360; GE HealthCare, Milwaukee, WI, USA). As for PDFF map, five circular regions of interests (ROIs) about 100 mm² were drawn manually in PDFF maps using the AW4.6 workstation (GE HealthCare, Milwaukee, WI, USA). Among them, three ROIs were evenly placed on right lobe and two on left, avoiding major vessels, ligaments and bile ducts[14]. The mean proportion of liver fat >5.5% was considered the main outcome of interest[15].

2.3. Construction and validation of a clinical nomogram

We carried out multivariable logistic regression analysis with the following candidate clinical parameters: age, gender, BMI, disease behavior, disease duration, Crohn's disease activity index (CDAI) and biochemical indicators. We applied backward step-wise selection and used the likelihood ratio test, considering Akaike's information criterion (AIC) as the ending criteria. Akaike information criterion is usually performed to assessed the goodness of fit of the model. To equip the clinicians with a quantitative tool to predict individual probability of NAFLD, we created a clinical nomogram based on multivariable logistic analysis in this primary cohort.

Discrimination of the prediction models was evaluated by receiver operating characteristics (ROC) analysis and presented as area under the curve (AUC). Odds ratios (OR) having 95% confidence intervals (CI) of final predictors were calculated. Calibration curves were used to assess the calibration of nomograms by comparing the predicted and observed probabilities[16]. The clinical effectiveness of the models was assessed using decision curve analysis (DCA)[17]. The nomogram performance was validated by ten-fold cross-validation with bootstrap.

2.4. Statistical analysis

Data were presented as mean (SDs) or median (interquartile range [IQRs]) for continuous variables and as number of cases and proportions for categorical ones. We employed multivariable stepwise logistic regression analysis to identify the features that best discriminate NAFLD. The input features consisted of the 9 disease-related parameters and then a feature elimination step was performed with minimum AIC method to select the top features and optimize the model. The operating characteristic curves (ROC) were plotted and area under curve (AUC) was calculated to assess the diagnostic performance of the model with the pROC package.

Other statistical analysis included non-parametric Mann-Whitney U-test, test of proportions or Pearson chi-square tests. A P value level less than 0.05 was considered nominally significant. All graphic and statistical analyses were conducted either using R statistical software (v4.0.3) or STATA/SE, version 16.

3. Results

3.1. Clinical characteristic

After application of inclusion and exclusion criteria, there were 340 CD subjects who were eligible for analysis, 86 patients of whom were diagnosed with NAFLD according to the MR result. The prevalence of NAFLD among the CD patients of this Chinese cohort was 24.8% (83/340). A flow diagram illustrating the process is presented in Fig. 1.

As shown in Table 1, the duration of CD was significantly longer than those without NAFLD ($P = 0.01$), though the gender and age at diagnosis were comparable between groups. The gender ratio was also nearly identical among groups. With regard to body mass index, those with NAFLD had a higher BMI than those without NAFLD ($P < 0.01$). Furthermore, there was no difference in the presence of metabolic syndrome and disease behavior or location.

Table 1
Demographics and clinical characteristics at baseline

	Non-NAFLD (n = 257)	NAFLD (n = 83)	P-value
Gender (M, %)	178(69.3)	64(77.1)	0.21
Age, yr	30 ± 11	32 ± 11	0.07
BMI, kg/m ²	19.6 ± 2.7	22.3 ± 4.5	<0.01
Current smoker	9(3.5)	2(2.4)	1.00
MS	18(7)	29(34.9)	<0.01
Disease duration, yr	2(0.8-5)	4(1-7)	0.01
CDAI	134(73-251)	130(65-246)	0.57
Active CD	125(48.6)	36(43.4)	0.45
Disease location	98(38.1)	38(45.8)	0.25
L1	11(4.3)	4(4.8)	0.77
L2	148(57.6)	41(49.4)	0.37
L3	161(62.6)	49(59)	0.60
P			
Disease Behavior	150(58.4)	42(50.6)	-
B1	61(23.7)	25(30.1)	-
B2	46(17.9)	16(19.3)	0.40
B3			
CRP	0.6(0.5-5.6)	0.6(0.5-5.3)	0.72
Alb	46.7(41.8-50.2)	46.1(42.9-49.3)	0.98
PAB	220(166.5-263)	256(197.1-292.9)	<0.01
ALT	14(10-22)	23.8(16-36)	<0.01
AST	18(15-22)	22(17-27)	<0.01
GGT	16(12.4-23)	26(15-41)	<0.01
5-ASA	146(56.8)	49(59)	0.63
AZA	107(41.7)	41(49.4)	0.06
Corticosteroids	96(37.4)	38(45.8)	0.04
Prolonged anti-TNF-α antibody use	151(58.8)	51(61.4)	0.70
TNF-α (ELISA)	272.7 ± 320.8	222.9 ± 303.1	0.59
IL-6(ELISA)	5.3 ± 4.3	4.3 ± 2.8	0.39
Values presented as Mean ± SD with t-test; Median [P25, P75] with Wilcoxon rank sum test, or N (%) with Pearson's chi-square test.			

Note: SD, standard deviation; BMI, body mass index; MS, metabolic syndrome; NAFLD, non-alcoholic liver disease; CRP, C- reactive protein; TP, total protein; Alb, albumin; PAB, prealbumin; ALT, Alanine

aminotransferase; AST, Aspartate aminotransferase; GGT, γ -glutamyl transpeptidase; 5-ASA, 5-Aminosalicylic acid; AZA, Azathioprine; TNF- α , tumor necrosis factor α ; IL-6, Interleukin-6.

3.2. Laboratory result

As for laboratory examination, no significant differences were found in the C-reaction protein level ($P = 0.72$), or albumin level ($p = 0.98$). However, it is significantly different in the level of liver function enzyme, such as ALT, AST, GGT ($P < 0.01$), as well as the level of prealbumin ($P < 0.01$).

3.3. Medication

No differences were observed between the groups with regard to receiving prolonged anti-TNF- α antibody ($P = 0.7$), with 51 of 83 (61.4%) in the NAFLD cohort and 151 of 257 (58.8%) in the CD only cohort. Furthermore, there was no difference in use of 5-aminosalicylic acid ($P = 0.63$) and azathioprine ($P = 0.06$) in the 2 groups. However, the NAFLD group has significantly more patients who received corticosteroid treatment ($p = 0.04$).

3.4. Model development

The results from multivariate logistic regression analysis showed that BMI (OR, 1.233, 95% CI, 1.136–1.34; $P = 0.001$), ALT (OR, 1.037, 95% CI, 1.009–1.065; $P = 0.009$), AST (OR, 1.023, 95% CI, 1.009–1.065; $P = 0.009$), GGT (OR, 1.016, 95% CI, 1.003–1.028; $P = 0.007$) were robust predictors of risk of NAFLD, based on which, the final prediction model were developed. The model consisted of disease duration, BMI, ALT, AST, GGT and prealbumin and the diagnostic equation was: $\text{logit}(P) = (-6.865) + \text{duration} \times (-0.057) + \text{BMI} \times (0.21) + \text{ALT} \times (0.036) + \text{AST} \times (-0.051) + \text{GGT} \times (0.015) + \text{PAB} \times (0.005)$ (Table 2).

Table 2
Multivariate Analysis for Factors Associated with NAFLD in CD Patients

Variable	Coefficient	OR (95%CI)	P-value
Duration	0.057	1.059(0.99-1.133)	0.097
BMI	0.21	1.233(1.136-1.34)	0.001
ALT	0.036	1.037(1.009-1.065)	0.009
AST	-0.051	0.954(0.904-0.993)	0.023
GGT	0.015	1.016(1.003-1.028)	0.014
PAB	0.005	1.005(1.001-1.008)	0.007
Intercept	-6.865	-	-
Values of OR>1 indicate a direct relationship, values <1 an inverse association.			

Note: NAFLD, non-alcoholic fatty liver disease; CD, Crohn's disease; OR, odd ratio; BMI, body mass index; ALT, Alanine aminotransferase; GGT, γ -glutamyl transpeptidase; PAB, Prealbumin.

A nomogram including these six parameters was presented to calculate the risk probability of NAFLD (Fig. 2). Receiver operating curve analysis shows that the area under ROC curve of model was 0.754 (Fig. 3), indicating the diagnostic performance was good. The calibration curve showed that the mean error was 0.021 (Fig. 4). DCA showed that within a very broad range for thresholds, the nomogram would bring net benefit in clinical practice (Fig. 5).

4. Discussion

Crohn's disease is a remitting and chronic disease that often involves the small intestine[18]. Thus, a complication of malnutrition and malabsorption is frequently occurred. However, since a study first reported an association between "an expanded fatty liver" and "ulceration of the colon" in 1873[19], there has been several studies conducted to further study the

link between the diseases. The prevalence of NAFLD in CD is reported to vary between 8.2–39.5%[5][20][21], depending on the diagnostic tools and criteria applied. And previous studies have proposed several factors associated with the NAFLD, including ethnic, BMI, disease duration[10], anti-TNF- α therapy[21] and etc. However, these studies were mostly conducted in a western population.

Our study recruited a group of Chinese patients diagnosed with CD, who completed MR during hospitalization, based on which the liver fat was imaging and calculated. Several implications can be highlighted from this research. Firstly, the prevalence of non-alcoholic liver disease is estimated to be 24.8% in CD patients, according to the standard of MR-PDFF > 5.5%, higher than the overall prevalence of 17% in China and Japan area[22]. This is consistent with a previous study reported in Japan, which reported a prevalence of 21.8%[20]. Although the age between groups did not differ significantly, there was a trend that the patients with NAFLD were older than the other group. CD patients with NAFLD presented longer disease duration, which is in accordance with the previous study[6]. This may be explained by the dysbiosis of gut bacteria due to the intestinal inflammation. Besides, the NAFLD group had a higher BMI and more frequent presence of metabolic syndrome.

Another finding is that there is no significant difference in the long-term use of anti-TNF- α between groups. Ambiguous results have been reported in the previous research[23][21]. However, both studies did not evaluate the long-term effect. In this study, we specifically document the times of patients receiving anti-TNF- α therapy, and did not find significantly difference in the occurrence of NAFLD in patients with prolonged anti-TNF- α use.

Liver fat content can be accurately and noninvasively detected through imaging examinations, such as ultrasound, computed tomography or magnetic resonance imaging. Among these tests to diagnose NAFLD, ultrasound and CT share close sensitivity and reliably identify steatosis when the liver comprises $\geq 20\%$ of fat. Although MRI can identify as little as 5% steatosis, the cost is much more higher[24]. Therefore, a clinical classifier is needed to evaluate the risk for NAFLD in a convenient, cost-effective manner, then to elevate patient compliance.

Applying logistic regression analysis, our model incorporates six parameters: BMI, prealbumin, ALT, AST, GGT and duration. The model has a high AUC value, which is indicative of greater sensitivity and specificity. The Hosmer-Lemeshow test shows that the model's predicted value does not differ significantly from the actual one. The C-index value is 0.753, indicating good consistency of our model. The model's calibration slope demonstrates a value of 0.834 after bias correction. The nomogram is a method with superiority widely used by oncologists to predict tumor prognosis. In current research, we have successfully created a visualized nomogram to predict the risk of developing NAFLD.

The major advantages of our study include the diagnosis of NAFLD based on MR-PDFF, use of a large cohort of CD patients, first to evaluate the long-term effect of use of anti-TNF- α on NAFLD. Nevertheless, several limitations need to be addressed. First, due to the retrospective nature, we defined NAFLD through chart review rather than prospectively collected the liver content data. Second, this is a monocentric research, which may limit the application of the diagnostic model. Further studies are warranted to assess if and how the immune dysfunction plays a role in liver steatosis.

5. Conclusion

In conclusion, our data report a comprehensive investigation of prevalence of NAFLD in Chinese population, which is high in chronic CD patients. And long-term use of anti TNF- α seems to have no effect on the progression of NAFLD in Chinese population. We also develop a nomogram to instruct clinical practice.

List Of Abbreviations

CD, Crohn's disease; NAFLD, non-alcoholic liver disease; IBD, inflammatory bowel disease; MRE, magnetic resonance enterography; T2DM, type 2 diabetes mellitus; CKD, chronic kidney diseases; BMI, body mass index; AIC, Akaike's information criterion; ROC, operating characteristic curves; DCA, decision curve analysis.

Declarations

Acknowledgement

Not applicable.

Funding

Supported by grants from National Natural Science Foundation of China (No. 81500424 & 81770545) and MDT Project of Clinical Research Innovation Foundation, Renji Hospital, School of Medicine, Shanghai Jiao Tong University (PYI-17-003).

Availability of data and materials

The datasets used and/or analyzed during the current study are included in its supplementary information files.

Authors' contributions

Contributed substantially to study conception and design, data acquisition, data analysis and interpretation: QJH, QF, JS, QZ, YQQ. Involved in drafting the manuscript or revising it critically: QJH, YQQ. Gave final approval of the version to be published: QJH, QF, JS, QZ, YQQ. Agreed to be held accountable: YQQ. All authors read and approved the final manuscript

Ethics approval and consent to participate

All methods were performed in accordance with the Declaration of Helsinki and approved by Shanghai Jiaotong University, School of Medicine, Renji Hospital Ethics Committee. As it is a retrospective cohort study, informed consent is waived, which is granted by the Shanghai Jiaotong University, School of Medicine, Renji Hospital Ethics Committee. (KY-2021-122-B).

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

References

1. Laass MW, Roggenbuck D, Conrad K. **Diagnosis and classification of Crohn's disease.** *Autoimmun Rev.* 2014;**13**:467–71.
2. Kaplan GG. **The global burden of IBD: from 2015 to 2025.** *Nat Rev Gastroenterol Hepatol.* 2015;**12**:720–7.
3. Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. **ACG Clinical Guideline: Management of Crohn's Disease in Adults.** *Am J Gastroenterol.* 2018;**113**:481–517.
4. Balestrieri P, Ribolsi M, Guarino MPL, Emerenziani S, Altomare A, Cicala M. **Nutritional Aspects in Inflammatory Bowel Diseases.** *Nutrients.* 2020;**12**:E372.
5. McHenry S, Sharma Y, Tirath A, Tsai R, Mintz A, Fraum TJ, et al. **Crohn's Disease Is Associated With an Increased Prevalence of Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study Using Magnetic Resonance Proton Density Fat Fraction Mapping.** *Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc.* 2019;**17**:2816–8.
6. Glassner K, Malaty HM, Abraham BP. **Epidemiology and Risk Factors of Nonalcoholic Fatty Liver Disease Among Patients with Inflammatory Bowel Disease.** *Inflamm Bowel Dis.* 2017;**23**:998–1003.
7. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. **Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.** *Nat Rev Gastroenterol Hepatol.* 2018;**15**:11–20.
8. Byrne CD, Targher G. **NAFLD: A multisystem disease.** *J Hepatol.* 2015;**62**:S47–64.

9. Saroli Palumbo C, Restellini S, Chao C-Y, Aruljothy A, Lemieux C, Wild G, et al. **Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography.** *Inflamm Bowel Dis.* 2019;**25**:124–33.
10. McHenry S, Tirath A, Tsai R, Sharma Y, Flores AG, Davidson NO, et al. **Derivation and Internal Validation of a Clinical Prediction Tool to Predict Nonalcoholic Fatty Liver Disease in Patients With Crohn's Disease.** *Inflamm Bowel Dis.* 2020. <https://doi.org/10.1093/ibd/izz324>.
11. Ran Z, Wu K, Matsuoka K, Jeen YT, Wei SC, Ahuja V, et al. **Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology practice recommendations for medical management and monitoring of inflammatory bowel disease in Asia.** *J Gastroenterol Hepatol.* 2021;**36**:637–45.
12. Bargiggia S, Maconi G, Elli M, Molteni P, Ardizzone S, Parente F, et al. **Sonographic prevalence of liver steatosis and biliary tract stones in patients with inflammatory bowel disease: study of 511 subjects at a single center.** *J Clin Gastroenterol.* 2003;**36**:417–20.
13. Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V, et al. **ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications.** *J Crohns Colitis.* 2019;**13**:144–64.
14. Piazzolla VA, Mangia A. **Noninvasive Diagnosis of NAFLD and NASH.** *Cells.* 2020;**9**:E1005.
15. Tang A, Tan J, Sun M, Hamilton G, Bydder M, Wolfson T, et al. **Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis.** *Radiology.* 2013;**267**:422–31.
16. **Assessing the calibration of mortality benchmarks in critica... Critical Care Medicine.** https://journals.lww.com/ccmjournals/Abstract/2007/09000/Assessing_the_calibration_of_mortality_benchmarks.7.aspx. Accessed 2 Sep 2021.
17. **A simple, step-by-step guide to interpreting decision curve analysis | Diagnostic and Prognostic Research | Full Text.** <https://diagnprognres.biomedcentral.com/articles/10.1186/s41512-019-0064-7>. Accessed 2 Sep 2021.
18. Torres J, Mehandru S, Colombel J-F, Peyrin-Biroulet L. **Crohn's disease.** *Lancet Lond Engl.* 2017;**389**:1741–55.
19. Nguyen NH, Singh S, Sandborn WJ. **Positioning Therapies in the Management of Crohn's Disease.** *Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc.* 2020;**18**:1268–79.
20. Sagami S, Ueno Y, Tanaka S, Fujita A, Hayashi R, Oka S, et al. **Significance of non-alcoholic fatty liver disease in Crohn's disease: A retrospective cohort study.** *Hepatol Res Off J Jpn Soc Hepatol.* 2017;**47**:872–81.
21. Sourianarayanan A, Garg G, Smith TH, Butt MI, McCullough AJ, Shen B. **Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease.** *J Crohns Colitis.* 2013;**7**:e279-285.
22. Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J, et al. **Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.** *J Hepatol.* 2018;**69**:896–904.
23. Likhitsup A, Dundulis J, Ansari S, Patibandla S, Hutton C, Kennedy K, et al. **High prevalence of non-alcoholic fatty liver disease in patients with inflammatory bowel disease receiving anti-tumor necrosis factor therapy.** *Ann Gastroenterol.* 2019;**32**:463–8.
24. Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. **Mechanisms of NAFLD development and therapeutic strategies.** *Nat Med.* 2018;**24**:908–22.

Figures




Figure 1

Flow diagram of the study design.




Figure 2

Nomograms for predicting risk of NAFLD.




Figure 3

The area under receiver operating curve (AUC)




Figure 4

Calibration plot




Figure 5

Decision curve analysis (DCA)

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [prevalence.csv](#)